To generate a chronic lymphocytic leukemia(CLL)mouse model with intact immune competence and short latency by adoptively transferring(AT)splenocytes from immunoglobulin heavy-chain enhancer-driven T-cell leukemia/lymphoma 1(Eμ-TCL1)transgenic donors into wild-type(WT)recipients. The gene discussed is SLC3A2; the disease is B-cell chronic lymphocytic leukemia.